Masters of Health Magazine May 2021 | Page 27

Safe in Occupied Spaces

The low concentrations of HP emitted by the CASPR Compact are safe and in fact currently found in many medical and household products, e. g. cosmetics, toothpastes, and deodorants. HP is a reactive, short-lived polar substance that has no expected bioaccumulation. In a risk evaluation, the EPA assumes a maximum half-life of half an hour for residual HP vapor.

Low Concentration Provided by CASPR is Highly Effective

Although the CASPR photocatalyst cells synthesize and dispense just traces of HP, the anti-microbial impact is highly effective.

Testing in a controlled environment with a prototype of the CASPR Compact situated on a tabletop inside a modular room 8 ft from various pathogen carriers, indicates that the CASPR device materially reduces or eliminates microorganisms on surfaces.

Results from a cycle of up to 24 hours show:

· Bacteria on carrier surfaces were reduced over 99.998%

·        Fungi were reduced over 95%

· Methicillin Resistant Staphylococcus (MRSA) was reduced over 99.98%

·       Influenza A (H1N1) was reduced over 99.93%, and

·        MS2 (virus) was reduced over 99.993%.

In a University of Wisconsin test, a CASPR unit reduced SARS-CoV-2 contamination by 99.991%.

CASPR Compact is a proven, safe, easy to use, low maintenance addition to the critical slate of risk reduction protocols. Along with other proven methods will greatly reduce risks for acquiring pathogens such as SARS-CoV2. 

The above was taken from a recently published White Paper “De-densifying Aerosols in Indoor Environments with CASPR Technology” by Dr. Margaret Scarlett.

You can read the entire White Paper here.

About the Author

Dr. Margaret Scarlett, DMD is a national and international expert on infection control, consultant to the World Health Organization, the Pan American Health Organization and international ministries of health, as well as global dental schools. She is the originator of the first infection control guidelines for dentistry from the Centers for Disease Control and Prevention (CDC) where she served 17 years. For the last twenty years, she has led teams in the veteran-owned small business that is a contractor to CDC and other US government agencies and private consumer health businesses on infectious and chronic disease management. Prior to retiring from CDC, Dr. Scarlett was a Senior Policy Analyst in the Office of the Assistant Secretary, Surgeon General, Office of Public Health and Science, Department of Health and Human Services from 1998-2000.

She has more than 23 years of experience with oral health policy, research and practice and has published 24 articles and a book chapter on oral health